At AION Healthspan our goal is to extend healthy years of life by restoring organ function through rigorously tested, regenerative‑medicine therapies. Every clinical program is built on the conviction that medicine should repair, not simply maintain.
Active Trial: REJUVXL™ for Chronic Kidney Disease
We are currently enrolling adults with Stage 3 Chronic Kidney Disease (CKD) in a first‑in‑human study at the University of Miami Health System.
- Investigational therapy – REJUVXL is an allogeneic cell product delivered as a brief intravenous infusion, similar in procedure to a blood transfusion.
- No anti‑rejection drugs required – The cells are designed to avoid immune rejection, eliminating the need for long‑term immunosuppression.
- Study objective – Assess safety while evaluating whether REJUVXL can slow, or potentially reverse, kidney decline and reduce the risk of dialysis or transplantation.
If you or a loved one has Stage 3 CKD, please visit our Clinical Trials page or speak with your nephrologist for details.
Programs in Development
Building on the same scientific platform, we are actively exploring patient studies for:
- Acute Respiratory Distress Syndrome (ARDS)
- Chronic Obstructive Pulmonary Disease (COPD)
- Acute Graft‑Versus‑Host Disease (GVHD)
Additional information—including study locations, eligibility criteria, and timelines—will be posted here as plans advance.
This page is intended for general information and does not replace professional medical advice. Always consult your healthcare provider before making healthcare decisions or considering participation in a clinical trial.
Please visit for more information on this trial: https://clinicaltrials.gov/study/NCT06721143